Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Amish community helps unlock genetic secrets of drug response

NCT ID NCT02891954

Summary

This study aims to understand why people respond differently to a common diabetes medication called canagliflozin. Researchers are giving the drug to 700 healthy volunteers of Amish descent and measuring how their bodies react. By comparing these reactions to each person's genetic makeup, they hope to find genetic markers that could one day help doctors predict which patients will benefit most from this type of medication.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

Explore the condition pages connected to this study.